Chat GPT answer as to possible reasons for the development

New Post Public Reply Private Reply Replies (1) Message Board
MGK_2 Katangolo #145415
1,032
Chat GPT answer as to possible reasons for the development of these anti-drug anti-bodies
Quote:
"When using adeno-associated virus (AAV) technology to deliver a gene that allows the body to produce a therapeutic protein like leronlimab, the immune system can sometimes recognize the newly produced protein as foreign, leading to the production of antibodies against it. Here’s why this might happen:

Immune System Recognition: Even though leronlimab is a therapeutic antibody designed to target specific human proteins, it's still possible for the immune system to recognize it as foreign, especially if it's being produced in a way that is atypical for the body. This recognition could lead to the development of anti-drug antibodies (ADAs).

Protein Structure Differences: The AAV vector might cause slight variations in how leronlimab is produced compared to how it would be if manufactured outside the body. These structural differences, even if minor, could make the protein appear foreign to the immune system.

Pre-existing Immunity: If a person has previously been exposed to leronlimab (e.g., through previous treatments), their immune system might have developed memory B cells that quickly produce antibodies against leronlimab upon re-exposure.

Autoimmunity or Breakdown of Tolerance: In rare cases, the body's tolerance mechanisms might fail, leading the immune system to target proteins that are actually self-made, which could include therapeutically produced proteins like leronlimab.

Vector Immunogenicity: The AAV vector itself can sometimes trigger an immune response, and this can lead to a broader immune activation that might include the production of antibodies against the delivered therapeutic protein.

In summary, the production of anti-leronlimab antibodies after using AAV technology could result from the immune system's recognition of the newly produced protein as foreign, potential structural differences in the protein, or broader immune responses triggered by the gene therapy vector."


So, in consideration of this, I suspect that if you dose LL weekly, those anti-drug antibodies would attack the leronlimab that was subcutaneously injected as well as the leronlimab that was produced inside the body. This of course would weaken RO and I don't know if you could still guarantee 100% RO in such a situation.

In order for the immune system to develop antibodies at all, something had to tell the system that the leronlimab it was seeing was foreign. The leronlimab manufactured outside the body is not typically perceived as foreign and anti-drug antibodies are not typically a problem when subcutaneously injected.

i'd suspect that it has more to do with the difference in the produced leronlimab within the body vs. the injected leronlimab that is causing the development of these antibodies.

Auto-immune disease really is a ramped up immune system against yourself. For some reason, your immune system thinks some part of your body is foreign and then develops a response against it. Well maybe these individuals have an Active Immune System and possibly, what you're suggesting, giving LL along side to bring it down to normal, might prevent that development of anti-drug antibodies.

Maybe we will find the answer in the coming Inflammation / Immune Activation Trial

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sweco: Europe’s Water Resilience Faces Tough Challenges

Updated Category News Views 102

Tackling Europe's Water Resilience Ah, water infrastructure—it's that unglamorous pillar we often overlook until nature reminds us of its importance, sometimes with a swift, wet slap across the face. Sweco's recent report might not grab flashy headlines, but it's a good reminder for Europe that smarter investments in water resilience ain't just good advice; it's a damn...

Continue Reading
OPC Energy Refinances $825M for U.S. Power Plants

Updated Category News Views 40

Strategic Financial Move for OPC Energy Here's the scoop from the powerhouse behind some major U.S. electricity moves: OPC Energy and its subsidiary CPV nailed down a hefty $825 million financing package for the Shore and Maryland power plants. This isn’t just any old financial shuffle. Nope, they've hammered out an all-in-one refinancing deal that's setting the stage...

Continue Reading
Trump Quotation Book Takes Unbiased Approach

Updated Category News Views 58

In the ever-evolving dance of political discourse, a new book strides onto the stage: Not My President, published by Palmetto Publishing. It’s a bold compilation of presidential utterances, capturing the words of Donald J. Trump in all their unvarnished glory. Stripped of analysis or comedic flair, each entry stands alone like a solitary figure at a cocktail party,...

Continue Reading
Quanta Services Reports Record Q3 2026 Earnings

Updated Category News Views 79

Quanta Services Smashes Q3 2026 Expectations If you're a stakeholder in Quanta Services, you'd probably be dancing in the aisles right now. This company just posted off-the-charts numbers for the third quarter of 2026. We're talking revenues of $12 billion—a staggering leap from $7.63 billion the same quarter last year. Explosive Earnings and Strong Backlog The star of...

Continue Reading
NIIT Expands with Bluewater: AI-Led Workforce Revolution

Updated Category News Views 39

Big Moves in Talent Transformation There's a shakeup in the learning space, folks, and it's all about building a more AI-driven future. Today we're dissecting how NIIT Learning Systems Limited, a name that rings a bell in global managed learning, just snapped up Bluewater Learning. Not just a small fry acquisition, oh no—this one's got some meaty implications, tallying...

Continue Reading
ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

Updated Category News Views 51

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

Continue Reading
Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Updated Category News Views 86

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...

Continue Reading
AI, GLP-1, and the Food Revolution Unveiled

Updated Category News Views 100

How the Food Industry Faces a Formulation Shake-Up In a world where diets are shifting like never before, food companies are adjusting their game plans or risk getting left in the dust. With one in five U.S. households reportedly housing a GLP-1 user by May 2026, the food game looks more like a strategic chess match than ever. Balancing taste, nutrition, and price is no...

Continue Reading
SKE Invigorates IRONWORKS London's Music Vibe With E-Cigs

Updated Category News Views 80

Bringing SKE's Flair to London's Music Scene Well, folks, hold onto your hats—SKE's thrown its weight behind IRONWORKS London, extending its reach deeper into the UK's electronic music scene. This ain't just another gig; we're talking about the second time SKE is flexing its sponsorship muscles in the UK music arena, officially angling for the vape category spotlight....

Continue Reading
Landstar Faces Legal Storm Post Earnings Miss

Updated Category News Views 17

Landstar's Earnings Misstep Sends Shockwaves Alright, let's talk about this snafu at Landstar (NASDAQ: LSTR). They were supposed to deliver an earnings sheet that's all roses, but instead, we got a couple of thorns. Analysts were expecting them to strike gold with EPS numbers between $1.62 to $1.67. What we got? A measly $1.42. Not exactly the shiny haul we were led to...

Continue Reading

Top 5 Most Recently Viewed Articles

Euronext Reports Impressive Trading Volumes for October 2025

Updated Category News Views 197

Euronext Reports Impressive Trading Volumes for October 2025 As the leading European capital market infrastructure, Euronext has made headlines by announcing its trading volumes for the month of October 2025. The announcement is crucial, as it provides insights into market trends and investor activities across its multiple exchanges. Overview of Trading Volumes During the...

Continue Reading
Amaroq Minerals Updates on Voting Rights and Share Capital

Updated Category News Views 114

Overview of Amaroq Minerals' Voting Rights Amaroq Minerals Ltd., an independent corporation focused on mine development, is making significant strides in the gold and strategic minerals sector with its extensive land holdings in Southern Greenland. The company has recently announced notable updates concerning its total voting rights and the issuance of shares. Recent...

Continue Reading
Ramaco Eyes Steel Market at StoneX Resource Summit

Updated Category News Views 6

Ramaco's Panel Discussion: A Market Indicator? Mark your calendars, because Ramaco Resources is stepping into the limelight at the StoneX Fourth Annual Natural Resources Summit in New York City. You’ve got Jeremy Sussman, the CFO, gearing up to hit the stage and chew over the state of the steel and metallurgical coal markets. With the summit running from June 9 to 10,...

Continue Reading
German Labor Market Shows Signs of Continued Weakness

Updated Category News Views 58

Challenges in the German Labor Market Recent research has unveiled that German companies are showing a marked reluctance to hire new staff, reaching the lowest level of employment motivation seen in over four years. The data, derived from the Ifo institute, underscores the prevailing challenges in Europe's largest economy. Decline in Hiring Intentions The Ifo employment...

Continue Reading
Cohen & Steers Expands Portfolio with Recent Shopping Center Acquisition

Updated Category News Views 95

Cohen & Steers Advances Retail Investments Cohen & Steers Income Opportunities REIT, Inc. (CNSREIT) has taken a significant step forward in its investment strategy by acquiring Village on Pooler Parkway, a community shopping center designed for open-air shopping. This move highlights CNSREIT's dedication to investing in high-quality, necessity-driven retail spaces located...

Continue Reading